Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “RESPIRATORY TRACT”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 145 records · Page 8Linked to original sources
PubMed2006

Rapid detection and clinical features of infants and young children with acute lower respiratory tract infection due to respiratory syncytial virus.

During December to the end of February of 2003 and 2004, a total of 282 nasopharyngeal aspirates were obtained from infants and young children admitted to the Buraidah Maternity and Pediatric Hospital, Al-Qassim, Saudi Arabia, and clinically diagnosed as suffering from acute lower respiratory tract infections. The aspirates were tested for the presence of respiratory syncytial virus using direct fluorescein-labeled monoclonal antibody assay. Of the 282 specimens, 128 (45.4%) were found to be positive for respiratory syncytial virus. The most positive specimens came from patients less than one year old (51.3%), and were associated with bronchopneumonia (56.7%) or bronchiolits (55.4%). Coughing (100%) and tachpnea (98%) were significantly more frequent in infants with respiratory syncytial virus infection, followed by wheezing, crepitation and retraction, each representing 66%. Three deaths were reported. The availability of a rapid viral diagnostic assay will be an important tool for physicians to make more accurate treatment decisions and therefore reduce unnecessary antibiotic usage and hospital stay for the patients.

Age Factors↗
PubMed2006

[Reasons for recurrent respiratory tract inflammations in children].

Respiratory tract inflammations are among the most frequent diseases in children. In natural conditions, respiratory tract is constantly prone to environmental pathogens. In fighting the respiratory tract infections both non-specific and specific: humoral and cellular immune mechanisms, related to mucosa-associated lymphoid tissue (MALT), take part. In healthy subjects, the upper respiratory tract is affluent in physiological bacterial flora comprising aerobic and anaerobic bacteria, some of them potentially pathogenic. In periods of reduced immunity they can cause endogenous infections. Contrary to the upper, the lower respiratory ways are physiologically sterile. The imbalance between defense mechanisms and pathogenity of microorganisms can lead to the development of infection. Recurrent respiratory tract inflammations, due to complexity of their causes, are a problem of great importance. Early estimation of the etiology of recurrent inflammations is particularly crucial, as it allows introduction of aimed therapy and prophylactics, thus preventing the child from the development of irreversible pulmonary lesions and impairment of physical development.

Child↗
PubMed2001

Clinical resistance encountered in the respiratory surveillance program (RESP) study: a review of the implications for the treatment of community-acquired respiratory tract infections.

The Respiratory Surveillance Program (RESP) is a large-scale surveillance study of potential bacterial pathogens from respiratory tract infections that was performed over a 10-month period (July to April) during the 1999-2000 respiratory infection season. It is also the first study of its kind to derive its information entirely from community-based medical practices. This study, therefore, provides insight into the identity, frequency, and susceptibility of the possible pathogens isolated from patients encountered by primary care physicians. Reduction of antibiotic susceptibility in various bacterial pathogens may be of academic interest. However, it is only the emergence of clinical resistance (strains exhibiting minimum inhibitory concentrations above the resistance breakpoint) to commonly used antibacterial agents in the most prevalent species that has significant impact on empiric therapy choices. A review of data from RESP indicated that the most prevalent species were Moraxella catarrhalis, Haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae. As expected, the prevalence of these bacterial isolates varied by disease state. The prevalence of clinical resistance to various antibiotics ranged, within these 4 species, between 0% and 92%. Resistance to the greatest number of drugs was expressed by S pneumoniae, followed by S aureus, H influenzae, and M catarrhalis. The prevalence of antibiotic resistance found among these community-isolated pathogens was surprisingly similar to that reported in hospital-based studies, suggesting that resistance is as important an issue in the community as it is in hospitals. With few exceptions, the prevalence of resistance was fairly uniform across disease states. The antibiotics most likely to encounter clinically resistant isolates during the treatment of community-acquired respiratory tract infections were penicillins, macrolides, and trimethoprim/sulfamethoxazole. The antibiotics least likely to encounter resistance were quinolones, followed by ceftriaxone and amoxicillin/clavulanate.

Anti-Bacterial Agents↗
PubMed1988

Respiratory muscle weakness during upper respiratory tract infections.

Global respiratory muscle strength was studied in 22 normal healthy volunteers during a 4-month winter period. Twelve subjects developed naturally acquired upper respiratory tract infections. Maximal static expiratory and inspiratory mouth pressures fell significantly during these infections. The greatest falls were documented between the third and seventh days of clinical illness. Full recovery occurred by the fourteenth day. We conclude that significant abnormalities of respiratory muscle function can occur during upper respiratory tract infections in otherwise healthy young adults.

Adult↗
PubMed2004

Comparative antimicrobial susceptibility of respiratory tract pathogens.

Bacterial respiratory tract infections (RTIs), whether primary or subsequent to viral infection, are a frequent cause of morbidity and mortality worldwide. Treatment of these infections is most often empirical. Therefore, an antimicrobial's antibacterial spectrum must include the most likely pathogens: Streptococcus pneumoniae, the most frequent cause of community-acquired pneumonia (CAP), Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus, as well as atypicals such as Mycoplasma pneumoniae, Legionella pneumophila and Chlamydophila (Chlamydia) pneumoniae. In addition, knowledge of antimicrobial resistance among these key pathogens is imperative for physicians to choose the most appropriate therapeutic agent. The latest data from global surveillance studies indicates that high-level resistance to penicillin (MIC > or =2 mg/l) among isolates of S. pneumoniae varies widely by geographic location. Rates exceed 20% in the USA, Mexico, Japan, Saudi Arabia, Israel, Spain, France, Greece, Hungary, and the Slovak Republic. In South Africa, Hong Kong, Taiwan, and South Korea rates exceed 50%. Penicillin non-susceptibility--including isolates exhibiting high-level resistance and intermediate susceptibility (MIC 0.12-1 mg/l)--is frequently found in association with macrolide resistance, which is found at a prevalence of 70-80% in some Asian countries. Trimethoprim-sulfamethoxazole (TMP-SMX) and tetracycline resistance, either individually or combined with macrolide resistance as multiple resistance, is also associated with reduced susceptibility to penicillin. Another concern about antimicrobial resistance in respiratory tract pathogens is beta-lactamase production among isolates of H. influenzae and M. catarrhalis. However, respiratory fluoroquinolones, of which levofloxacin has been available for the longest time, currently remain active against the great majority of common bacterial respiratory pathogens, including atypicals.

Bacterial Infections↗
PubMed1998

The pattern of micro-organisms and the efficacy of new macrolide in acute lower respiratory tract infections.

Lower respiratory tract infection (LRTI) is one of the major health problems in developing countries such as Indonesia. According to the National Household Health Survey conducted by the Ministry of Health in 1992, LRTIs still rank fourth as the main cause of death in Indonesia. The problem of LRTIs could be simply managed as long as the causative organism can be identified and the proper antibiotic known. In some occasions, it is not quite so easy to identify the causative micro-organism, especially in lower tract infections. There are several methods of obtaining specimens from LRTIs for cultures. The easiest, most simple way is to collect expectorated sputum. Unfortunately, because of the high rate of contamination by upper respiratory tract flora, this method is not reliable. Recognizing the difficulties with routine expectorated sputum cultures, two alternative approaches have been suggested. One approach is to bypass potential expectorated sputum 'contaminants' in the oropharynx by transtracheal aspiration or transthoracic aspiration. The second approach is to modify the usual technique of processing expectorated sputum by either washing techniques or by quantitative cultures. Azithromycin and clarithromycin are chemically related to macrolide erithromycin. Both antibiotics retain the traditional macrolide spectrum of activity against gram-positive and atypical pneumonia pathogens, while demonstrating improved activity against gram-negative bacteria. The American Thoracic Society (ATS) recommended the use of macrolide for outpatients with community-acquired pneumonia, without comorbidity and 60 years of age or younger. A total of 34 outpatients with acute LRTIs were open-comparative, randomly allocated to treatment with the new macrolide in Persahabatan Hospital, Jakarta, 1996. The purposes of this study were: (i) to identify the causative micro-organisms; and (ii) to evaluate the clinical efficacy of the new macrolide in these infections. Azithromycin 500 mg was given orally once a day for 3 days and was administered 1 h before or 2 h after every meal. Clarithromycin 500 mg was given orally every 12 h for 10 days. The diagnosis of the patients were: 16 with pneumonia, 10 with acute bronchitis and 8 with acute exacerbation of chronic bronchitis. In this study of 34 patients, the sputum specimens were washed with N acetylcysteine before culture and we could only detect micro-organisms in one patient. Before treatment, we found 47 strains in 33 (97.05%) patients and after treatment we found five strains. From serological examination, only four (11.76%) atypical bacterial were detected. The most frequently found microorganisms were 23 strains of Klebsiella pneumoniae (40.42%), 10 of Streptococcus alpha haemolyticus (21.26%), five of Streptococcus pneumoniae (10.63%) and five of Staphylococcus aureus (10.63%). The atypical bacterial were: two Legionella pneumophila, one Mycoplasma pneumoniae and one Chlamydia pneumoniae. The clinical efficacy of new macrolides were 100% and the bacteriological responses with eradication of 94.12% vs 70.59% of isolates in the azithromycin and clarithromycin groups are shown in Table 1. There were no adverse reactions detected in the two treatment groups until the end of the study.

Administration, Oral↗
PubMed1979

[Respiratory tract diseases in coal miners. II. Chronic non-specific respiratory tract diseases in coal miners].

Miners of two coal mines were examined: mine "A"--2094 miners and mine "B"--1846 miners working underground. Both the examined population and work environment were thoroughly described in part I. Medical examinations involved disease history and occupational inquiry on a special questionnaire form, a part of this questionnaire being based on the BMRC questionnaire. In addition, spirometric examinations were conducted, VC, FEV1 was determined, and chest was X-rayed. Average PNChUO rate in both populations under examinations came to 16.5%; in the "A" mine it was significantly higher (19.1%), compared to the "B" mine--(13.5%). Obturative PNChUO constituted, on average, 1.7% of the total PNChUO rate in both mines and occurred more frequently in the "B" mine (2.1%), where work was more mechanized than in the "A" mine (1.3%). The highest PNChUO percentage was found in those working at most dusted work--stands. The PNChUO rate in its obturative form was found to be directly proportional to age and length of employment. No effect of PNChUO on the quality and rate of changes in EKG in those suffering from this disease was found.

Adult↗
PubMed1996

Common (but not always considered) viral infections of the lower respiratory tract.

Viral lower respiratory tract infections continue to cause a great deal of morbidity and mortality in the United States and worldwide, despite advances in treatment options, chemoprophylaxis, and vaccine development. The availability of ribavirin has improved the outlook in high-risk patients who develop respiratory syncytial virus bronchiolitis while intensive efforts are continued to develop an efficacious and safe vaccine. Respiratory syncytial virus immunoglobulin may prove to be a useful tool in the armamentarium of the pediatrician to prevent or modify respiratory syncytial virus disease in individual patients. Influenza vaccination and chemoprophylaxis remain mainstays in the prevention of influenza disease in high-risk individuals. The availability of a vaccine for varicella and a wider dissemination of measles vaccine, particularly in developing nations, may well limit the adverse outcomes associated with pneumonias caused by these two viruses. The transplant patient and other immunocompromised patients will continue to challenge clinicians and scientists to provide innovative and effective therapies for viral infections. The exciting advances in clinical and research virology over the last decade offer much hope to practicing pediatricians who struggle with offering prevention strategies and treatment options for their patients. Viral lower respiratory tract infections will never be eliminated as a clinical problem, although the morbidity and mortality associated with them will continue to improve.

Adenoviridae Infections↗